317 related articles for article (PubMed ID: 14648018)
21. Hepatocellular carcinoma cell lines from diethylnitrosamine phenobarbital-treated rats. Characterization and sensitivity to endothall, a protein serine/threonine phosphatase-2A inhibitor.
Thièry JP; Blazsek I; Legras S; Marion S; Reynes M; Anjo A; Adam R; Misset JL
Hepatology; 1999 May; 29(5):1406-17. PubMed ID: 10216123
[TBL] [Abstract][Full Text] [Related]
22. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
23. Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines.
Bijnsdorp IV; Kruyt FA; Fukushima M; Smid K; Gokoel S; Peters GJ
Cancer Sci; 2010 Feb; 101(2):440-7. PubMed ID: 19886911
[TBL] [Abstract][Full Text] [Related]
24. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Avallone A; Di Gennaro E; Bruzzese F; Laus G; Delrio P; Caraglia M; Pepe S; Comella P; Budillon A
Anticancer Drugs; 2007 Aug; 18(7):781-91. PubMed ID: 17581300
[TBL] [Abstract][Full Text] [Related]
25. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
[TBL] [Abstract][Full Text] [Related]
26. P21Cip1 is a critical mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells.
Geller JI; Szekely-Szucs K; Petak I; Doyle B; Houghton JA
Cancer Res; 2004 Sep; 64(17):6296-303. PubMed ID: 15342418
[TBL] [Abstract][Full Text] [Related]
27. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
28. The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?
McCluskey A; Ackland SP; Gardiner E; Walkom CC; Sakoff JA
Anticancer Drug Des; 2001 Dec; 16(6):291-303. PubMed ID: 12375882
[TBL] [Abstract][Full Text] [Related]
29. [Effects of RNA interference and nolatrexed on thymidylate synthase expression and cell proliferation of human colorectal carcinoma LOVO cells].
Tian SB; Jing CQ; Li LP
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Nov; 15(11):1187-91. PubMed ID: 23172536
[TBL] [Abstract][Full Text] [Related]
30. An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed.
Graham-Cole CL; Thomas HD; Taylor GA; Newell DR; Melton RG; Hesp R; Boddy AV
Cancer Chemother Pharmacol; 2007 Feb; 59(2):197-206. PubMed ID: 16721548
[TBL] [Abstract][Full Text] [Related]
31. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
Tumber A; Collins LS; Petersen KD; Thougaard A; Christiansen SJ; Dejligbjerg M; Jensen PB; Sehested M; Ritchie JW
Cancer Chemother Pharmacol; 2007 Jul; 60(2):275-83. PubMed ID: 17124594
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A.
Shan HB; Cai YC; Liu Y; Zeng WN; Chen HX; Fan BT; Liu XH; Xu ZL; Wang B; Xian LJ
Anticancer Drugs; 2006 Sep; 17(8):905-11. PubMed ID: 16940800
[TBL] [Abstract][Full Text] [Related]
33. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.
Welsh SJ; Titley J; Brunton L; Valenti M; Monaghan P; Jackman AL; Aherne GW
Clin Cancer Res; 2000 Jun; 6(6):2538-46. PubMed ID: 10873110
[TBL] [Abstract][Full Text] [Related]
34. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.
Verheul HM; Qian DZ; Carducci MA; Pili R
Cancer Chemother Pharmacol; 2007 Aug; 60(3):329-39. PubMed ID: 17256134
[TBL] [Abstract][Full Text] [Related]
35. Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin.
Geller J; Petak I; Szucs KS; Nagy K; Tillman DM; Houghton JA
Clin Cancer Res; 2003 Dec; 9(17):6504-15. PubMed ID: 14695155
[TBL] [Abstract][Full Text] [Related]
36. Enhanced antitumor activity of 5-fluorouracil in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts.
Ciccolini J; Peillard L; Evrard A; Cuq P; Aubert C; Pelegrin A; Formento P; Milano G; Catalin J
Clin Cancer Res; 2000 Apr; 6(4):1529-35. PubMed ID: 10778986
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of thymidylate synthase activity by antisense oligodeoxynucleotide and possible role in thymineless treatment.
Lin SB; Ts'o PO; Sun SK; Choo KB; Yang FY; Lim YP; Tsai HL; Au LC
Mol Pharmacol; 2001 Sep; 60(3):474-9. PubMed ID: 11502877
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines.
Rakitina TV; Vasilevskaya IA; O'Dwyer PJ
Biochem Pharmacol; 2007 Jun; 73(11):1715-26. PubMed ID: 17343830
[TBL] [Abstract][Full Text] [Related]
39. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines.
Tanaka R; Ariyama H; Qin B; Takii Y; Baba E; Mitsugi K; Harada M; Nakano S
Cancer Chemother Pharmacol; 2005 Jun; 55(6):595-601. PubMed ID: 15731917
[TBL] [Abstract][Full Text] [Related]
40. DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status.
Adamsen BL; Kravik KL; De Angelis PM
Int J Oncol; 2011 Sep; 39(3):673-82. PubMed ID: 21674128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
